MOMO'S BREAKOUT BOARD

[pumpnass]

$NBIO just put out an 8-k

On March 31, 2021, the Company entered into a license agreement with BioRay Pharmaceutical Co Ltd granting a license for commercialization of the Company’s antibody Pritumumab internationally excluding North and Central America. Under terms of the agreement, the Company will receive US $5,000,000 at various milestones commencing with the initial payment received on April 20, 2021 of US $1,000,000. An additional payments of $750,000 will be received upon enrollment of the 12th patient in the phase 1 clinical trial which has enrolled its first cohort. Upon approval for phase 2 clinical trials from the United States Food and Drug Administration, the Company will receive $2,500,000. When the phase 2 trials begin the balance of $750,000 will be received.


https://ih.advfn.com/stock-market/USOTC/nascent-biotech-qb-NBIO/stock-news/85073323/current-report-filing-8-k